Revenue Breakdown
Composition ()
No data
Revenue Streams
Apellis Pharmaceuticals Inc (APLS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Licensing and other revenue, accounting for 61.2% of total sales, equivalent to $280.82M. Other significant revenue streams include SYFOVRE and EMPAVELI. Understanding this composition is critical for investors evaluating how APLS navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Apellis Pharmaceuticals Inc maintains a gross margin of 94.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 48.67%, while the net margin is 47.04%. These profitability ratios, combined with a Return on Equity (ROE) of 14.10%, provide a clear picture of how effectively APLS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, APLS competes directly with industry leaders such as SUPN and ERAS. With a market capitalization of $2.94B, it holds a significant position in the sector. When comparing efficiency, APLS's gross margin of 94.65% stands against SUPN's 77.47% and ERAS's N/A. Such benchmarking helps identify whether Apellis Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
